cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.14469/hpc/11017
title: The Houk–List transition states for organocatalytic mechanisms revisited. Table 4
DOI: 10.14469/hpc/11018
title: The Houk–List transition states for organocatalytic mechanisms revisited. Table 5
DOI: 10.14469/hpc/11019
title: The Houk–List transition states for organocatalytic mechanisms revisited. Table 6
DOI: 10.14469/hpc/11020
title: The Houk–List transition states for organocatalytic mechanisms revisited. Table 7
DOI: 10.14469/hpc/11021
title: The Houk–List transition states for organocatalytic mechanisms revisited. Table 8
DOI: 10.6084/m9.figshare.20580024
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580024.v1
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580036
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580036.v1
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580084
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580084.v1
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580087
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580087.v1
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580771
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580771.v1
title: Supplementary Material for: A Retrospective Chart Review of 809 Patients With Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices

description: Introduction: This analysis reports demographic and clinical characteristics of patients with physician-diagnosed essential thrombocythemia (ET) receiving cytoreductive therapy in US community clinical practice. Methods: Patient characteristics, medical history, diagnostic test results, signs/symptoms, treatment patterns, and physician practice settings were extracted from medical charts for patients with physician-diagnosed ET receiving cytoreductive therapy. Results: Among 809 patients (51.1% female; 75.4% White; median age, 69 years) from 50 community practices, 64.5% had physician-reported diagnosis per World Health Organization criteria. Only 48.8% underwent diagnostic bone marrow biopsies; 87.5% had JAK2 mutation testing. Among those tested, 512/708 (72.3%), 57/213 (26.8%), and 37/213 (17.4%) had JAK2, CALR, and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8%). Of those who discontinued, 65.9% received no subsequent therapy and had higher ET symptom rates at last visit versus patients continuing HU (48.8% vs 25.0%). Conclusion: This study shows notable gaps in ET diagnosis and management. Half of patients were diagnosed without bone marrow biopsy, many received incorrect risk assignment, and the majority who discontinued HU received no subsequent therapy despite continued need.
DOI: 10.6084/m9.figshare.20580920
title: Additional file 1 of Reducing costs for DNA and RNA sequencing by sample pooling using a metagenomic approach

description: Additional file 1. Supplemental material.
DOI: 10.6084/m9.figshare.20580920.v1
title: Additional file 1 of Reducing costs for DNA and RNA sequencing by sample pooling using a metagenomic approach

description: Additional file 1. Supplemental material.
DOI: 10.6084/m9.figshare.20580948
title: Additional file 1 of Extracting multiple surfaces from 3D microscopy images in complex biological tissues with the Zellige software tool

description: Additional file 1: Supplementary Notes 1-5. Note 1. Overview of Zellige implementation. Note 2. Generation of phantom 3D images. Note 3. Comparing the reconstructed and ground truth height maps. Note 4. Sensitivity Analysis. Note 5. Computational/processing time of Zellige. Table S1. Zellige parameters.
DOI: 10.6084/m9.figshare.20580948.v1
title: Additional file 1 of Extracting multiple surfaces from 3D microscopy images in complex biological tissues with the Zellige software tool

description: Additional file 1: Supplementary Notes 1-5. Note 1. Overview of Zellige implementation. Note 2. Generation of phantom 3D images. Note 3. Comparing the reconstructed and ground truth height maps. Note 4. Sensitivity Analysis. Note 5. Computational/processing time of Zellige. Table S1. Zellige parameters.
DOI: 10.6084/m9.figshare.16683101
title: Additional file 1 of Inequalities in population health loss by multiple deprivation: COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in Scotland

description: Additional file 1.
DOI: 10.6084/m9.figshare.16683101.v1
title: Additional file 1 of Inequalities in population health loss by multiple deprivation: COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in Scotland

description: Additional file 1.
DOI: 10.6084/m9.figshare.20581019
title: Additional file 10 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 10.
DOI: 10.6084/m9.figshare.20581019.v1
title: Additional file 10 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 10.
DOI: 10.6084/m9.figshare.20581034
title: Additional file 5 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 5.
DOI: 10.6084/m9.figshare.20581034.v1
title: Additional file 5 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 5.
DOI: 10.6084/m9.figshare.20581037
title: Additional file 6 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 6.
DOI: 10.6084/m9.figshare.20581037.v1
title: Additional file 6 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 6.
DOI: 10.6084/m9.figshare.20581040
title: Additional file 7 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 7.
DOI: 10.6084/m9.figshare.20581040.v1
title: Additional file 7 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 7.
DOI: 10.6084/m9.figshare.20581043
title: Additional file 8 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 8.
DOI: 10.6084/m9.figshare.20581043.v1
title: Additional file 8 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 8.
DOI: 10.6084/m9.figshare.20581046
title: Additional file 9 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 9.
DOI: 10.6084/m9.figshare.20581046.v1
title: Additional file 9 of Location-specific signatures of Crohn’s disease at a multi-omics scale

description: Additional file 9.
DOI: 10.6084/m9.figshare.20581047
title: Additional file 1 of A tool for predicting overall survival in patients with Ewing sarcoma: a multicenter retrospective study

description: Additional file 1: Figure S1. Kaplan-Meier survival curve in the validation set.
DOI: 10.6084/m9.figshare.20581047.v1
title: Additional file 1 of A tool for predicting overall survival in patients with Ewing sarcoma: a multicenter retrospective study

description: Additional file 1: Figure S1. Kaplan-Meier survival curve in the validation set.
DOI: 10.6084/m9.figshare.20581094
title: Additional file 5 of A developmental role for the chromatin-regulating CoREST complex in the cnidarian Nematostella vectensis

description: Additional file 5. Analyzed mass spec data.
DOI: 10.6084/m9.figshare.20581094.v1
title: Additional file 5 of A developmental role for the chromatin-regulating CoREST complex in the cnidarian Nematostella vectensis

description: Additional file 5. Analyzed mass spec data.